The success of drug discovery depends on the content of the compound library. 

Since existing libraries are biased towards historical targets, new protein targets suffer from low hit rates.

To break this vicious cycle, CARMOLEX Inc has developed enabling technologies for the large-scale design, synthesis and validation of small molecule protein antagonists, providing the largest chemical libraries available in the world to our clients drug discovery projects.